Industry Insights
November 30, 2022. 2022 saw continued investment in emerging players and big strategic bets by many established life sciences software platforms. From clinical discovery to commercialization, advancing digital solutions remains central to pharma and med device manufacturers. The plethora of real world evidence data collected pre-market and post-market continues to demand innovation and a data analytics ecosystem where both software and services players co-exist. We are excited about the huge potential for further strategic consolidation and high growth opportunities for many new entrants.